Incyte Corporation(INCY) Stock Research - Grey Stern Research
Loading...

Incyte Corporation (INCY) Stock Analysis

$83.38 (1.26%)

INCY Financial Performance


Use the table below to view Incyte Corporation's financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2024

Metric Value Ranking among Peers
Price $83.38 -
52 Week Low $50.35 -
52 Week High $83.94 -
Market Cap $16.1 Billion 5/18
Gross Margin 92% 4/18
Profit Margin 9% 6/18
EBITDA margin 16% 4/18
Q3 - 2024 Revenue $1.1 Billion 1/18
Q3 - 2024 Earnings $106.5 Million 3/18
Q3 - 2024 Free Cash Flow $293.2 Million 2/18
Trailing 4 Quarters Revenue $4.1 Billion 2/18
Trailing 4 Quarters Earnings $32.5 Million 5/18
Quarterly Earnings Growth -38% 15/18
Annual Earnings Growth -96% 15/18
Quarterly Revenue Growth 24% 11/18
Annual Revenue Growth 8% 14/18
Cash On Hand $1.3 Billion 4/18
Short Term Debt $3.9 Million 15/18
Long Term Debt $28.2 Million 15/18

Incyte Corporation Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Incyte Corporation's metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 494.52 1/18
PS 3.94 14/18
PB 5.07 14/18
PC 12.32 14/18
Liabilities to Equity 0.58 12/18
ROA 0.01 5/18
ROE 0.01 6/18
Current Ratio 2.72 7/18
Quick Ratio 0.96 10/18
Long Term Debt to Equity 0.01 16/18
Debt to Equity 0.01 17/18
Burn Rate -12.50 16/18
Cash to Cap 0.08 4/18
CCR 2.75 2/18
EV to EBITDA 82.26 7/18
EV to Revenue 3.63 14/18

Company Details

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

CEO: Mr. Herve Hoppenot

Website: https://www.incyte.com

Address: 1801 Augustine Cut off Wilmington, DELAWARE

Exchange: NASDAQ Global Select

Industry: Biotechnology

Incyte Corporation Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Incyte Corporation. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
ImmunoGen, Inc. IMGN $8.7 Billion
Amicus Therapeutics, Inc. FOLD $3.3 Billion
Alnylam Pharmaceuticals, Inc. ALNY $35.8 Billion
BioMarin Pharmaceutical Inc. BMRN $12.8 Billion
ACADIA Pharmaceuticals Inc. ACAD $2.9 Billion
Ionis Pharmaceuticals, Inc. IONS $6.2 Billion
BeiGene, Ltd. BGNE $23.0 Billion
Denali Therapeutics Inc. DNLI $4.5 Billion
Sarepta Therapeutics, Inc. SRPT $11.6 Billion
Arrowhead Pharmaceuticals, Inc. ARWR $2.7 Billion
Ultragenyx Pharmaceutical Inc. RARE $4.6 Billion
United Therapeutics Corporation UTHR $18.3 Billion
argenx SE ARGX $35.6 Billion
Apellis Pharmaceuticals, Inc. APLS $3.7 Billion
Axsome Therapeutics, Inc. AXSM $4.3 Billion
Harmony Biosciences Holdings, Inc. HRMY $2.1 Billion
Prometheus Biosciences, Inc. RXDX $9.6 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
INCY Income Statements
Quarter Year Revenue Earnings
Q3 2024 $ 1.1 Billion $106.5 Million
Q2 2024 $ 1.0 Billion -$444.6 Million
Q1 2024 $ 880.9 Million $169.5 Million
Q4 2023 $ 1.0 Billion $201.1 Million
Q3 2023 $ 919.0 Million $171.3 Million
Q2 2023 $ 954.6 Million $203.5 Million
Q1 2023 $ 808.7 Million $21.7 Million
Q4 2022 $ 926.7 Million $28.5 Million

View All

INCY Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q3 2024 $1.3 Billion $5.0 Billion $32.2 Million $3.2 Billion
Q2 2024 $987.3 Million $4.7 Billion $37.5 Million $3.0 Billion
Q1 2024 $3.3 Billion $7.1 Billion $32.6 Million $5.4 Billion
Q4 2023 $3.2 Billion $6.8 Billion $38.3 Million $5.2 Billion
Q3 2023 $3.2 Billion $6.4 Billion $31.9 Million $4.9 Billion
Q2 2023 $3.1 Billion $6.2 Billion $39.7 Million $4.7 Billion
Q1 2023 $2.8 Billion $5.8 Billion $32.8 Million $4.5 Billion
Q4 2022 $3.0 Billion $5.8 Billion $44.6 Million $4.4 Billion

View All

INCY Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2024 $293.2 Million -$17.7 Million $316.9 Million
Q2 2024 -$631.1 Million -$55.5 Million -$2.4 Billion
Q1 2024 $209.3 Million -$9.5 Million $132.6 Million
Q4 2023 $145.5 Million -$2.3 Million -$13.7 Million
Q3 2023 $0 $0 $0
Q2 2023 $299.2 Million -$7.3 Million $310.1 Million
Q1 2023 -$132.5 Million -$26.9 Million -$130.4 Million
Q4 2022 $262.4 Million -$21.3 Million $260.9 Million

View All